Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comment on: intra-aortic balloon pump can be used after acute type A aortic dissection repair.

Journal of cardiothoracic surgery·2026

Same author

Beyond alpha-stat and pH-stat: Perfusion adequacy as the primary goal in the era of goal directed perfusion.

Perfusion·2026

Same author

Genome-wide analyses of Mycobacterium tuberculosis complex isolates reveal insights into circulating lineages and drug resistance mutations in The Gambia.

Scientific reports·2026

Same author

Preoperative decision tree model for predicting pulmonary valve-sparing repair in humanitarian pediatric tetralogy of fallot patients.

Journal of cardiothoracic surgery·2026

Same author

Cryo-EM structures of NHEJ assemblies with nucleosomes.

Nature communications·2025

Same author

Metabolic control of porin permeability influences antibiotic resistance in Escherichia coli.

Nature microbiology·2025

Same journal

Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven review.

Drug discovery today·2026

Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026

Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026

Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026

Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026

Same journal

From biologics to small-molecule modulators: the evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Targeting tuberculosis using structure-guided fragment-based drug design.

Vitor Mendes¹, Tom L Blundell¹

¹Department of Biochemistry, University of Cambridge, Cambridge CB21GA, UK.

Drug Discovery Today

|October 16, 2016

Summary

This summary is machine-generated.

Fragment-based drug discovery yields small molecule inhibitors for various diseases. This approach is gaining traction for tuberculosis research, with ongoing efforts to develop new antimycobacterial compounds.

More Related Videos

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

Related Experiment Videos

Last Updated: Mar 13, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

Area of Science:

Medicinal Chemistry
Drug Discovery
Tuberculosis Research

Background:

Fragment-based drug discovery (FBDD) is a successful strategy for identifying small molecule inhibitors.
FBDD is widely applied in oncology and antimicrobial research, with marketed drugs like vemurafenib and venetoclax.
The application of FBDD in tuberculosis research remains limited.

Purpose of the Study:

To review the progress and challenges of FBDD for developing antimycobacterial compounds.
To highlight recent successes and future directions in anti-tuberculosis drug discovery using FBDD.

Main Methods:

Literature review of fragment-based approaches in tuberculosis research.
Analysis of successes and challenges in developing antimycobacterial agents via FBDD.

Main Results:

FBDD has yielded promising leads for tuberculosis, though clinical applications are sparse.
Several research groups are actively pursuing FBDD strategies against Mycobacterium tuberculosis.

Conclusions:

FBDD holds significant potential for discovering novel anti-tuberculosis drugs.
Overcoming current challenges is crucial for advancing FBDD in tuberculosis treatment.